COCRYSTALS - A NEW DRUG FORM
DOI:
https://doi.org/10.56782/pps.96Keywords:
cocrystals, cocrystallization, pharmaceutical cocrystals, API, methods of cocrystallizationAbstract
Cocrystallization was already known 160 years ago. Cocrystals are structurally homogeneous crystalline materials containing two or more components present in definite stoichiometric amounts. The components are discrete neutral molecular species which are solids at ambient temperature. The use of cocrystallization to generate new forms of active pharmaceutical ingredients (API) was initiated only at the end of the last century. In recent years, the number of publications on this topic has increased significantly, mainly because of the possibility of replacing poorly soluble salts of biologically active substances with their cocrystals. Of particular importance are the physicochemical properties of cocrystals which, when modified, alter the pharmacodynamic parameters of the cocrystallized drug. It is possible to improve the solubility, stability, and – in particular – the bioavailability of drugs.
Downloads
References
Friscic T., Jones W.: Benefits of cocrystalisation in pharmaceutical materials science: an update, Jourmal of Pharmacy and Pharmacology, 2010, 62, 1547-1559. DOI: https://doi.org/10.1111/j.2042-7158.2010.01133.x
Cheney M. L., Weyna D. R.,Shan N., Mazen H., Wojas Ł., Zaworotko M. J.: Supramolecular architectures of meloxicam carboxylic acid cocrystals, a crystal engineering case study, Crystal Growth and Design, 2010, 10, 4401-4413. DOI: https://doi.org/10.1021/cg100514g
Dunitz J. D.: Crystal and co-crystal: a second opinion, Crystal Engeeniring Communications, 2003, 5, 506-506. DOI: https://doi.org/10.1039/b315687g
Desiraju G. R.: Crystal and co-crystal, Crystal Engeenering Communications, 2003, 5, 466-467. DOI: https://doi.org/10.1039/b313552g
Bond A. D.: What is a co-crystal? Crystal Engeenering Communications, 2007, 9, 833-834. DOI: https://doi.org/10.1039/b708112j
Aakeröy C. B., Salmon D. J.: Building co-crystals with molecular sense and supramolecular sensibility, Crystal Engeenering Communications, 2005, 7,439-448. DOI: https://doi.org/10.1039/b505883j
Qiao N., Schlindwein W., Malek N., Davis A., Trappitt G.: Pharmaceutical cocrystals: an overview, International Journal of Pharmaceutics, 2011. 419, 1-11. DOI: https://doi.org/10.1016/j.ijpharm.2011.07.037
Dario Broga F. G.: Making Crystal by Design, Wiley-VCH Verlag GmbH & Co, KGaA, Weinheim, 2006.
Yadav A. V., Shete A. S., Dabke A. P., Kulkarni P. V., Sakhare S. S.: Co-crystals: A novel approach to modify physicochemical properties of active pharmaceutical ingredients, Indian Journal of Pharmaceutical Sciences, 2009, 71, 370-359. DOI: https://doi.org/10.4103/0250-474X.57283
Ling A. R., Baker J. L.: XCVI.—Halogen derivatives of quinone. Part III. Derivatives of quinhydrone, Journal of the Chemical Society, 1893, 63, 1314-1327. DOI: https://doi.org/10.1039/CT8936301314
Chadwick K., Davey R., Cross W.: How does grinding produce co-crystals? Insights from the case of benzophenone and diphenylamine, Crystal Engeenering Communications, 2007, 9, 732-734. DOI: https://doi.org/10.1039/b709411f
Karki S., Friščić T., Jones W., Motherwell W. D. S.: Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding, Molecular Pharmaceutics, 2007, 4, 347-354. DOI: https://doi.org/10.1021/mp0700054
Lien Nguyen K., Friščić T., Day G. M., Gladden L. F., Jones W.: Terahertz time-domain spectroscopy and the quantitative monitoring of mechanochemical cocrystal formation, Nature Materials, 2007, 6, 206-209. DOI: https://doi.org/10.1038/nmat1848
Rastogi R., Bassi P.S., Chadha S.: Mechanism of the reaction between hydrocarbons and picric acid in the solid state, Journal of Physical Chemistry, 1963, 67, 2569-2573. DOI: https://doi.org/10.1021/j100806a016
Shan N., Toda F., Jones W.: Mechanochemistry and cocrystal formation: efect of solvent on reaction kintetics, Chem. Commun. (Camb.), 2002, 20, 2372-2373.
Jayasankar A., Samwangthanaroj A., Shao Z. J., Rodriguez-Hornedo N.: Cocrystal formation during cogrinding and storage is mediated by amorphous phase, Pharmaceutical Research, 2006, 23, 2381-2392. DOI: https://doi.org/10.1007/s11095-006-9110-6
Friščić T., Jones W.: Recent advances in understanding the mechanism of cocrystal formation via grinding, Crystal Growth and Design, 2009, 1621-1637. DOI: https://doi.org/10.1021/cg800764n
Seefeldt K., Miller J., Alvarez-Nunez F., Rodriguez-Hornedo N.: Crystallization pathways and kinetics of carbamazepine–nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies, Journal of Pharmaceutical Sciences, 2007, 96, 1147-1158. DOI: https://doi.org/10.1002/jps.20945
Shan N., Toda F., Jones W.: Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics, Chemical Communications, 2002(20), 2372-2373. DOI: https://doi.org/10.1039/b207369m
Friščić T., Childs S. L., Rizvi S. A. A., Jones W.: The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome, Crystal Engeenering Communications, 2009, 11, 418-426. DOI: https://doi.org/10.1039/B815174A
Blagden N., Berry D. J., Parkin A., Javed H., Ibrahim A., Gavan P. T., De Matos L. L., Seaton C. C.: Current directions in co-crystal growth, New Journal of Chemistry, 2008, 32(10), 1659-1672. DOI: https://doi.org/10.1039/b803866j
Dhumal R. S., Biradar S. V., Paradkar A. R., York P.: Ultrasound assisted engineering of lactose crystals, Pharmaceutical Research, 2008, 25, 2835-2844 DOI: https://doi.org/10.1007/s11095-008-9653-9
Lipinski C.A.: Solubility in water and DMSO: Issues and potential solutions, AAPS Press, Arlington, USA, 2004.
Takagi T., Ramachandran C., Bermeio M., Yamashita S., Yu L. X., Amidon G. L.: A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan, Molecular Pharmaceutics, 2006, 3, 631-643 DOI: https://doi.org/10.1021/mp0600182
Good D. J., Rodríguez-Hornedo N.: Solubility advantage of pharmaceutical cocrystals, Crystal Growth and Design, 2009. 9, 2252-2264. DOI: https://doi.org/10.1021/cg801039j
Rasenack N., Hartenhauer H., Muller B. W.: Microcrystals for dissolution rate enhancement of poorly water-soluble drugs, International Journal of Pharmaceutics, 2003, 254, 137-145. DOI: https://doi.org/10.1016/S0378-5173(03)00005-X
Li Z. J., Abramow Y., Bordner J., Leonard J., Medek A., Trask A. V.: Solid-state acid-base interactions in complexes of heterocyclic bases with dicarboxylic acids: Crystallography, hydrogen bond analysis, and 15N NMR spectroscopy, Journal of the American Chemical Society, 2006, 128, 8199-8210. DOI: https://doi.org/10.1021/ja0541332
Hong J. Y., Kim J. K., Song Y. K., Park J. S., Kim C. K.: A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption, Journal of Controlled Release, 2006, 110, 332-338. DOI: https://doi.org/10.1016/j.jconrel.2005.10.002
Umeda Y., Fukami T., Furuishi T., Suzuki T., Tanjoh K., Tomono K.: Characterization of multicomponent crystal formed between indomethacin and lidocaine, Drug Development and Industrial Pharmacy, 2009, 35, 843-851. DOI: https://doi.org/10.1080/03639040802660489
Schultheiss N., Newman A.: Pharmaceutical cocrystals and their physicochemical properties, Crystal Growth and Design, 2009, 9, 2950-2967. DOI: https://doi.org/10.1021/cg900129f
Aakeröy C. B., Fasulo M. E., Desper J.: Cocrystal or salt: does it really matter? Molecular Pharmaceutics, 2007, 4, 317-322. DOI: https://doi.org/10.1021/mp060126o
McNamara D. P., Childa S. L., Giordani J., Iarriccio A., Cassidy J., Shet M. S., Mannion R., O’Donnell E., Park A.: Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API, Pharmaceutical Research, 2006, 23, 1888-1897. DOI: https://doi.org/10.1007/s11095-006-9032-3
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
